Skip to main
INSP

INSP Stock Forecast & Price Target

INSP Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 18%
Buy 47%
Hold 35%
Sell 0%
Strong Sell 0%

Bulls say

Inspire Medical Systems Inc. has demonstrated a significant increase in its spending on direct-to-consumer advertising, which rose by 56% in the third quarter of 2025 and is expected to continue into 2026, suggesting a strategic effort to boost awareness and procedure volumes for its neurostimulation technology targeting obstructive sleep apnea. The company has reiterated its revenue guidance for 2025, with a notable increase in GAAP earnings per share, reflecting improved operational performance. Furthermore, management indicated a projected rise in average selling prices due to improved reimbursement, positioning the company for higher revenue growth and profitability going forward.

Bears say

Inspire Medical Systems has faced challenges with the launch of its new product, Inspire 5, resulting in a revised revenue and earnings per share outlook due to slower-than-anticipated adoption rates. The company has also seen a decline in advertising expenditures for 2024 and into 1H25, further indicating a tightening budget and potential revenue struggles. Additionally, a reduction in operational expenditures, particularly in research and development and selling, general, and administrative expenses, points to a cautious approach amidst headwinds affecting future growth potential, leading to a negative outlook on the stock.

INSP has been analyzed by 17 analysts, with a consensus rating of Buy. 18% of analysts recommend a Strong Buy, 47% recommend Buy, 35% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Inspire Medical Systems Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Inspire Medical Systems Inc (INSP) Forecast

Analysts have given INSP a Buy based on their latest research and market trends.

According to 17 analysts, INSP has a Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $134.59, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $134.59, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Inspire Medical Systems Inc (INSP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.